A/S Genmab Acquires 120,752 Shares of Merus (NASDAQ:MRUS) Stock

Merus N.V. (NASDAQ:MRUS) major shareholder A/S Genmab bought 120,752 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was bought at an average price of $97.00 per share, with a total value of $11,712,944.00. Following the purchase, the insider owned 71,583,829 shares in the company, valued at $6,943,631,413. This trade represents a 0.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

A/S Genmab also recently made the following trade(s):

• On Wednesday, December 17th, A/S Genmab purchased 150,795 shares of Merus stock. The stock was purchased at an average cost of $97.00 per share, for a total transaction of $14,627,115.00.

Merus Price Performance

NASDAQ MRUS traded down $0.09 during trading on Thursday, reaching $96.80. The company’s stock had a trading volume of 820,454 shares, compared to its average volume of 1,275,767. The firm has a fifty day moving average of $95.57 and a 200 day moving average of $75.41. Merus N.V. has a one year low of $33.19 and a one year high of $96.99. The stock has a market capitalization of $7.34 billion, a PE ratio of -18.26 and a beta of 1.06.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Merus in a research note on Wednesday, October 8th. Lifesci Capital reiterated a “market perform” rating and issued a $97.00 target price on shares of Merus in a research report on Tuesday, September 30th. Leerink Partners restated a “market perform” rating and set a $97.00 price target (up previously from $95.00) on shares of Merus in a research report on Monday, October 6th. BMO Capital Markets reaffirmed a “market perform” rating and set a $97.00 price target on shares of Merus in a research note on Friday, October 31st. Finally, William Blair lowered Merus from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Three equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Merus currently has a consensus rating of “Hold” and a consensus price target of $93.56.

Hedge Funds Weigh In On Merus

Hedge funds and other institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC lifted its stake in shares of Merus by 199.1% in the 3rd quarter. FNY Investment Advisers LLC now owns 6,000 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 3,994 shares during the period. Hudson Bay Capital Management LP raised its holdings in Merus by 2,188.6% in the third quarter. Hudson Bay Capital Management LP now owns 740,394 shares of the biotechnology company’s stock worth $69,708,000 after purchasing an additional 775,843 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in Merus during the third quarter valued at $68,838,000. Swiss Life Asset Management Ltd purchased a new position in Merus during the third quarter valued at $238,000. Finally, Polar Asset Management Partners Inc. boosted its holdings in shares of Merus by 870.1% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $4,708,000 after buying an additional 44,846 shares in the last quarter. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.